Thymosin Alpha-1 + Thymalin

Overview

Vendor 'TA-1 Complex' blend combining Thymosin Alpha-1 (Zadaxin; approved in some countries for hepatitis B/C, not FDA-approved in the US) with Thymalin (a Russian calf-thymus polypeptide extract associated with the Khavinson research program). This blend is not clinically validated; no trials have studied the combination itself.

Mechanism of Action

Proposed (not validated) rationale: Thymosin Alpha-1 has documented effects on T-cell maturation in the context of viral infection; Thymalin is a heterogeneous peptide extract rather than a defined molecule, with evidence largely from older Russian literature. Combining them is a vendor marketing convention, not a pharmacologically rational co-formulation.

Research Summary

No clinical trials of the Thymosin Alpha-1 + Thymalin combination exist. Each component has its own regulatory and evidentiary context; pairing them as an injectable blend is not supported by published combination data.

Reported Side Effects

• See individual Thymosin Alpha-1 and Thymalin profiles

Frequently asked questions

How does Thymosin Alpha-1 + Thymalin work?

Proposed (not validated) rationale: Thymosin Alpha-1 has documented effects on T-cell maturation in the context of viral infection; Thymalin is a heterogeneous peptide extract rather than a defined molecule, with evidence largely from older Russian literature. Combining them is a vendor marketing convention, not a pharmacologically rational co-formulation.

What does the research say about Thymosin Alpha-1 + Thymalin?

No clinical trials of the Thymosin Alpha-1 + Thymalin combination exist. Each component has its own regulatory and evidentiary context; pairing them as an injectable blend is not supported by published combination data.